Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 7/20 | 0.47 |
| ▸ | ACACA | Q13085 | 7/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10232262 | 0.89 | NAMPT (0.55) | IRAK1NAMPTPRMT5ACACBACACA | |
| SCHEMBL10232155 | 0.87 | TRPA1 (0.55) | IRAK1NAMPTPRMT5SUV39H2CKS1B | |
| SCHEMBL803332 | 0.86 | CKS1B (0.56) | NAMPTACACBACACACKS1BSKP1 | |
| SCHEMBL11977739 | 0.83 | IRAK1 (0.47) | IRAK1NAMPTPRMT5ACACBACACA | |
| SCHEMBL786220 | 0.82 | PPARA (0.43) | F10TRPA1 | |
| SCHEMBL10230218 | 0.81 | CKS1B (0.59) | NAMPTACACBACACASUV39H2CKS1B | |
| SCHEMBL10230212 | 0.81 | CKS1B (0.59) | NAMPTACACBACACASUV39H2CKS1B | |
| SCHEMBL11977728 | 0.80 | IRAK1 (0.45) | IRAK1NAMPTPRMT5ACACBACACA | |
| SCHEMBL15728295 | 0.80 | TRPA1 (0.54) | NAMPTACACBACACASUV39H2CKS1B | |
| SCHEMBL23138432 | 0.79 | DRD2 (0.50) | NAMPTACACBACACACKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | IRAK1 567/4885NAMPT 3344/4885PRMT5 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.